Search NASA⌕ Search

Engineering topics

Pearson, D

Publications and source records attributed to Pearson, D.

SU-F-T-356: DosimetricComparison of VMAT Vs Step and Shoot IMRT Plans for Stage III Lung CancerPatients with Mediastinal Involvement

Purpose: For Stage III lung cancers that entail treatment of some or all of the mediastinum, anterior-posterior focused Step and Shoot IMRT (SS-IMRT) and VMAT plans have been clinically used to deliver the prescribed dose while working to minimize lung dose and avoid other critical structures. A comparison between the two planning methods was completed to see which treatment method is superior and minimizes dose to healthy lung tissue. Methods: Ten patients who were recently treated with SS-IMRT or VMAT plans for Stage III lung cancer with mediastinal involvement were selected. All patients received a simulation CT for treatment planning, as well as a 4D CT and PET/CT fusion for target delineation. Plans were prescribed 6250 cGy in 25 fractions and normalized such that 100% of the prescription dose covered 95% of the PTV. Clinically approved SS-IMRT or VMAT plans were then copied and planned using the alternative modality with identical optimization criteria. SS-IMRT plans utilized seven to nine beams distributed around the patient while the VMAT plans consisted of two full 360 degree arcs. Plans were compared for the lung volume receiving 20 Gy (V20). Results: Both SS-IMRT and VMAT can be used to achieve clinical treatment plans for patients with Stage III Lung cancer with targets encompassing the mediastinum. VMAT plans produced an average V20 of 23.0+/−8.3% and SS-IMRT produced an average of 24.2+/−10.0%. Conclusion: Results indicate that either method can achieve comparable dose distributions, however, VMAT can allow the optimizer to distribute dose over paths of minimal lung tissue and reduce the V20. Therefore, creating a VMAT with constraints identical to an SS-IMRT plan could help to reduce the V20 in clinical treatment plans.

60 APPLIED LIFE SCIENCES↗

SU-E-J-269: Assessing the Precision of Dose Delivery in CBCT-Guided Stereotactic Body Radiation Therapy for Lung and Soft Tissue Metastatic Lesions

Purpose: Ensuring reproducibility of target localization is critical to accurate stereotactic body radiation treatment (SBRT) for lung and soft tissue metastatic lesions. To characterize interfraction variability in set-up and evaluate PTV margins utilized for SBRT, daily CBCTs were used to calculate delivered target and OAR doses compared to those expected from planning. Methods: CBCT images obtained prior to each fraction of SBRT for a lung and thyroid metastatic lesion were evaluated. The target CTV/ITV and OARs on each of 8 CBCT data sets were contoured. Using MIM fusion software and Pinnacle{sup 3} RTP system, delivered dose distribution was reconstructed on each CBCT, utilizing translational shifts performed prior to treatment. Actual delivered vs. expected doses received by target CTV/ITV and adjacent critical structures were compared to characterize accuracy of pre-treatment translational shifts and PTV margins. Results: The planned CTV/ITV D95% and V100% were 4595cGy and 91.47% for the lung lesion, and 3010cGy and 96.34% for the thyroid lesion. Based on CBCT analysis, actual mean D95% and V100% for lung ITV were 4542±344.4cGy and 91.54±3.45%; actual mean D95% and V100% for thyroid metastasis CTV were 3005±25.98cGy and 95.20±2.522%. For the lung lesion, ipsilateral lung V20, heart V32 (cc) and spinal cord (.03 cc) max were 110.15cc, 3.33cc, and 1680cGy vs. 110.27±14.79cc, 6.74±3.76cc, and 1711±46.56cGy for planned vs. delivered doses, respectively. For the thyroid metastatic lesion, esophagus V18, trachea (.03 cc) max, and spinal cord (.03 cc) max were 0.35cc, 2555cGy, and 850cGy vs. 0.16±0.13cc, 2147±367cGy, and 838±45cGy for planned vs. delivered treatments, respectively. Conclusion: Minimal variability in SBRT target lesion dose delivered based on pre-treatment CBCT-based translational shifts suggests tighter PTV margins may be considered to further decrease dose to surrounding critical structures. Guidelines for optimal target alignment during CBCT-guidance for lung and soft tissue metastatic lesions treated with SBRT are being established.

60 APPLIED LIFE SCIENCES↗

SU-E-T-556: Dosimetric Comparison of the Bladder and Rectum Based On Daily CBCT for Prostate IMRT

Purpose: With the use of CBCT, delivered dose can be calculated by transferring the planned beams onto the CBCT. Bladder and rectum volumetric doses were calculated and correlated to the daily bladder and rectum fullness. Methods: Patients for this study underwent hypofractionated prostate IMRT to 70 Gy in 28 fractions. Daily CBCT was utilized for image guidance. A clinically acceptable plan was created using a CTV to PTV margin of 5mm. Image fusion was performed to transfer the bladder and rectum contours onto each CBCT. Contours were then edited to match the anatomy of each CBCT. Using the daily treatment isocenter, the planned beams were transferred onto the CBCT and daily and cumulative DVHs calculated. Results: At the time of planning the bladder volume was 470.66cc. The mean, minimum and maximum bladder volume from the 28 CBCTs was 230.57cc, 76.16 cc and 380.8 cc, respectively. Planned bladder V70Gy was 0.98%. Actual bladder V70Gy, as calculated from the CBCTs was 2.46±1.36%. Similarly, planned V60Gy, V50Gy and V40Gy were 2.55%, 4.15% and 6.35% of the total bladder volume. The observed volumes receiving 60Gy, 50Gy and 40Gy were 5.18±2.53%, 4 to 8.21±3.76% and 6 to 12.93±5.60%, respectively. On the planning CT the rectum volume was 41.5cc. The observed mean, minimum and maximum rectum volumes were 58.09cc, 93.52 and 47.50cc. The planned rectum V70Gy was 6.02% while the observed cumulative rectum V70Gy was 13.68±3.39%. Rectum V60Gy, V50Gy and V40Gy changed from 13.61% to 22.5±3.86%, 19.15% to 28.68±4.45 and 25.56% to 34.75±5.15%. Conclusion: Bladder and rectum volumes changes during treatment have an affect on the cumulative dose received by these organs. It was observed that volumetric dose received by bladder decreases as volume of the bladder increases. There is no particular trend observed between volumetric dose and rectal volume.

60 APPLIED LIFE SCIENCES↗

Engineering Prototype for a Compact Medical Dielectric Wall Accelerator

A compact accelerator system architecture based on the dielectric wall accelerator (DWA) for medical proton beam therapy has been developed by the Compact Particle Acceleration Corporation (CPAC). The major subsystems are a Radio Frequency Quadrupole (RFQ) injector linac, a pulsed kicker to select the desired proton bunches, and a DWA linear accelerator incorporating a high gradient insulator (HGI) with stacked Blumleins to produce the required acceleration energy. The Blumleins are switched with solid state laser-driven optical switches integrated into the Blumlein assemblies. Other subsystems include a high power pulsed laser, fiber optic distribution system, electrical charging system, and beam diagnostics. An engineering prototype has been constructed and characterized, and these results will be used within the next three years to develop an extremely compact 150 MeV system capable of modulating energy, beam current, and spot size on a shot-to-shot basis. This paper presents the details the engineering prototype, experimental results, and commercialization plans.

43 PARTICLE ACCELERATORS↗

A Single Pulse Sub-Nanosecond Proton RFQ

A Radio Frequency Quadrupole (RFQ) linac system has been developed to provide a single pulse of 2 MeV protons with a beam pulse width of {approx}300 ps and a charge of 30 pC, either for injection into a pulsed Dielectric Wall Accelerator or for bombardment of a target to produce a fast neutron pulse. The 1.2 m long RFQ structure operates at 425 MHz and bunches and accelerates a single 2.35 ns beam pulse injected into it at 35 keV using a parallel plate deflector placed directly in front of the RFQ entrance. The input acceptance properties of the RFQ allow a simple dc bias voltage on the plates to block acceleration of the unwanted beam, with a short rf voltage pulse applied to null the deflection field for the ions within the 8 mm 'kicker' plate length. The use of the RFQ as the accelerating structure allows one to efficiently produce a large charge in a single sub-ns bunch. In addition, the kicker can also be used without the dc bias voltage to produce a 'notch' in the normal RFQ output beam for synchrotron injection.

43 PARTICLE ACCELERATORS↗

ULTRA-COMPACT ACCELERATOR TECHNOLOGIES FOR APPLICATION IN NUCLEAR TECHNIQUES

We report on compact accelerator technology development for potential use as a pulsed neutron source quantitative post verifier. The technology is derived from our on-going compact accelerator technology development program for radiography under the US Department of Energy and for a clinic sized compact proton therapy systems under an industry sponsored Cooperative Research and Development Agreement. The accelerator technique relies on the synchronous discharge of a prompt pulse generating stacked transmission line structure with the beam transit. The goal of this technology is to achieve approx10 MV/m gradients for 10 s of nanoseconds pulses and approx100 MV/m gradients for approx1 ns systems. As a post verifier for supplementing existing x-ray equipment, this system can remain in a charged, stand-by state with little or no energy consumption. We describe the progress of our overall component development effort with the multilayer dielectric wall insulators (i.e., the accelerator wall), compact power supply technology, kHz repetition-rate surface flashover ion sources, and the prompt pulse generation system consisting of wide-bandgap switches and high performance dielectric materials.

43 PARTICLE ACCELERATORS↗

Compact Dielectric Wall Accelerator Development For Intensity Modulated Proton Therapy And Homeland Security Applications

Compact dielectric wall (DWA) accelerator technology is being developed at the Lawrence Livermore National Laboratory. The DWA accelerator uses fast switched high voltage transmission lines to generate pulsed electric fields on the inside of a high gradient insulating (HGI) acceleration tube. Its high electric field gradients are achieved by the use of alternating insulators and conductors and short pulse times. The DWA concept can be applied to accelerate charge particle beams with any charge to mass ratio and energy. Based on the DWA system, a novel compact proton therapy accelerator is being developed. This proton therapy system will produce individual pulses that can be varied in intensity, energy and spot width. The system will be capable of being sited in a conventional linac vault and provide intensity modulated rotational therapy. The status of the developmental new technologies that make the compact system possible will be reviewed. These include, high gradient vacuum insulators, solid dielectric materials, SiC photoconductive switches and compact proton sources. Applications of the DWA accelerator to problems in homeland security will also be discussed.

43 PARTICLE ACCELERATORS↗

COMPACT PROTON INJECTOR AND FIRST ACCELERATOR SYSTEM TEST FOR COMPACT PROTON DIELECTRIC WALL CANCER THERAPY ACCELERATOR

A compact proton accelerator for cancer treatment is being developed by using the high-gradient dielectric insulator wall (DWA) technology [1-4]. We are testing all the essential DWA components, including a compact proton source, on the First Article System Test (FAST). The configuration and progress on the injector and FAST will be presented.

43 PARTICLE ACCELERATORS↗

STATUS OF THE DIELECTRIC WALL ACCELERATOR

The dielectric wall accelerator (DWA) system being developed at the Lawrence Livermore National Laboratory (LLNL) uses fast switched high voltage transmission lines to generate pulsed electric fields on the inside of a high gradient insulating (HGI) acceleration tube. High electric field gradients are achieved by the use of alternating insulators and conductors and short pulse times. The system is capable of accelerating any charge to mass ratio particle. Applications of high gradient proton and electron versions of this accelerator will be discussed. The status of the developmental new technologies that make the compact system possible will be reviewed. These include, high gradient vacuum insulators, solid dielectric materials, photoconductive switches and compact proton sources.

43 PARTICLE ACCELERATORS↗